Türkkan Görkem, Alkan Ali, Paydaş Semra, Tanrıverdi Özgür, Karakaş Yusuf, Karadurmuş Nuri, Sakin Abdullah, Temiz Süleyman, Arpacı Erkan, Akın Mustafa, Menekşe Serkan, Şen Cenk Ahmet, Barışta İbrahim
Department of Radiation Oncology, Muğla Sıtkı Koçman University Medical Faculty, Muğla, Turkey.
Department of Medical Oncology, Muğla Sıtkı Koçman University Medical Faculty, Muğla, Turkey.
Indian J Hematol Blood Transfus. 2020 Oct;36(4):640-645. doi: 10.1007/s12288-020-01257-0. Epub 2020 Feb 22.
Marginal zone lymphomas (MZLs) are rare and indolent subtypes of non-Hodgkin lymphomas, and their clinical behaviours are heterogeneous. The aim of this study was to evaluate the clinical and prognostic characteristics of MZL. In this multicentre retrospective study, we analyzed demographical, clinical and prognostic features of 64 MZL patients. The median age was 54.0 and 78.1% of the patients had extra-nodal disease at presentation. Most of the patients were treated with chemotherapy. The 5 years and 10 years overall survival (OS) rates were 74.5% and 62.1%, respectively. The analysis of factors associated with OS showed that ECOG performance score was an important prognostic factor, with 133.0 months (95% CI 49.3-216.5) versus 18.0 months (95% CI 12.1-23.7) for ECOG 0-1 and 2-3, respectively (= 0.011). Prognosis of MZL is favorable and ECOG performance score was found associated with OS. Further detailed studies with large patient numbers are needed to clarify the clinical features and treatment management of MZLs.
边缘区淋巴瘤（MZL）是非霍奇金淋巴瘤中罕见且惰性的亚型，其临床行为具有异质性。本研究旨在评估MZL的临床和预后特征。在这项多中心回顾性研究中，我们分析了64例MZL患者的人口统计学、临床和预后特征。中位年龄为54.0岁，78.1%的患者在初诊时患有结外疾病。大多数患者接受了化疗。5年和10年总生存率（OS）分别为74.5%和62.1%。与OS相关因素的分析表明，ECOG体能状态评分是一个重要的预后因素，ECOG 0 - 1组的OS为133.0个月（95%CI 49.3 - 216.5），而ECOG 2 - 3组为18.0个月（95%CI 12.1 - 23.7）（P = 0.011）。MZL的预后良好，且发现ECOG体能状态评分与OS相关。需要进一步开展大样本量的详细研究以阐明MZL的临床特征和治疗管理。
